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Abstract 
Aims: Hydrogen sulfide (H2S) is a vasoactive gasotransmitter that is 
endogenously produced in the vasculature by the enzyme cystathionine γ-lyase 
(CSE). However, the importance of CSE activity and local H2S generation for 
ischemic vascular remodeling remains completely unknown. In this study, we 
examine the hypothesis that CSE critically regulates ischemic vascular 
remodeling involving H2S dependent mononuclear cell regulation of 
arteriogenesis. 
Methods and results: Arteriogenesis including mature vessel density, collateral 
formation; blood flow and SPY angiographic blush rate were determined in WT 
and CSEKO mice at different time points following femoral artery ligation (FAL). 
The role of endogenous H2S in regulation of IL-16 expression and subsequent 
recruitment of monocytes, and expression of VEGF and bFGF in ischemic 
tissues, were determined along with EPC (CD34/Flk1) formation and function. 
FAL of wild type mice significantly increased CSE activity, expression and 
endogenous H2S generation in ischemic tissues and monocyte infiltration, which 
was absent in CSEKO mice. Treatment of CSEKO mice with the polysulfide 
donor diallyl trisulfide (DATS) restored ischemic vascular remodeling, monocyte 
infiltration and cytokine expression. Importantly, exogenous H2S therapy restored 
NO bioavailability in CSEKO mice that was responsible for monocyte recruitment 
and arteriogenesis.   
Conclusion: Endogenous CSE/H2S regulates ischemic vascular remodeling 
mediated during hind limb ischemia through NO dependent monocyte 
recruitment and cytokine induction revealing a previously unknown mechanism of 
arteriogenesis. 
Key Words: Ischemia, hydrogen sulfide, nitric oxide, cystathionine γ-lyase, 
vascular remodeling, arteriogenesis.  
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Introduction 
 
Hydrogen sulfide (H2S) is a gasotransmitter that has many positive 
cardiovascular effects. H2S has recently been identified as an endogenously 
produced gaseous signaling molecule. H2S is synthesized by cystathionine γ-
lyase (CSE) and 3-mercaptopyruvate sulfur transferase (3-MST) in peripheral 
vascular tissues.1 CSE is recognized as the major enzyme that produces H2S 
with L-cysteine serving as the primary substrate. The CSE/H2S pathway 
mediates various physiological effects including angiogenesis, vasoregulation, 
neuromodulation, reducing oxidative stress, cytoprotection and cellular 
signaling.2 H2S signaling is impaired during regeneration of vascular tissue 
following ischemia.3 H2S has also both pro-inflammatory and anti-inflammatory 
properties, which are crucial for initiation and development of mature collaterals.4 
H2S promotes vascular smooth muscle relaxation and induces vasodilation of 
isolated blood vessels by opening K-ATP channels and induces angiogenesis by 
cross talk with nitric oxide (NO).5, 6 Furthermore, studies have suggested that H2S 
is endogenously synthesized by monocytes and macrophages, which in turn 
regulates the functions of these cells that may play roles in arteriogenesis.4 In 
addition, recently it was shown in a study that H2S induces EPC function and 
improves wound healing in type 2 diabetic mice.7 
Peripheral arterial disease (PAD) is a chronic occlusive disorder involving 
reduction of blood flow in the limbs that may lead to detrimental complications 
such as critical limb ischemia and limb amputation, and is associated with 
increased death due to involvement of other cardiovascular disorders.8, 9 
Additionally, patients with other cardiovascular disorders experience an 
increased prevalence of PAD.10 Therapeutic angiogenesis is one of the better 
treatment options for PAD, but multiple clinical trials have shown limited 
benefits.11 Neovascularization is a fundamental requirement for many 
pathophysiological conditions.12 It occurs through three distinct processes that 
include vasculogenesis13, angiogenesis or arteriogenesis3 via several 
intermediary-signaling molecules that enhance these processes.14 The changes 
in mechanical forces acting on the endothelial cells lining the premature arteries 
stimulate the inflammatory signals needed for the start of the collateral growth.15  
Patients with both PAD and other co-morbid disorders suffer from 
impaired arteriogenesis due to dysfunction in inflammatory cell monocytes.16 
Cytokines such as IL-16 have been shown as a pro-arteriogenic factor in mouse 
hind limb ischemia.17 Studies with human subjects have shown that impaired 
number and function of EPCs were observed in cardiovascular disease patients18 
including those with diabetes mellitus.19 However, mobilization and recruitment of 
EPCs were observed during ischemia and inflammation to enhance 
vasculogenesis.20 Ischemia can upregulate various other cytokines such as 
VEGF, SDF-1 and MCP-1 or interleukins that induce circulating EPCs and 
enhance revascularization. 21  
Thus, H2S and mononuclear cell infiltrates might be important for 
arteriogenesis and angiogenesis under ischemic conditions. In the present study, 
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we examined the importance of endogenous CSE/H2S during femoral artery 
ligation and their effects on ischemic vascular remodeling. 
 
Methods 
 
Animals and experimental procedures  
Twelve-week-old male C57BL/6J (WT) and Cystathionine γ-lyase knock out 
(CSE KO) mice were used in this study. Mice were maintained in strict 
accordance with the National Research Council’s Guide for Care and Use of 
Laboratory Animals. All animal studies were approved by the LSU Health-
Shreveport institutional animal care and use committee (approval # P-12-011). 
 
Induction of mouse critical limb ischemia model with treatment profiles 
Permanent hind limb ischemia was induced in WT and CSE KO mice as 
previously described.3 Mice were anesthetized with ketamine/xylazine (100 and 8 
mg/kg) injection and ligation of the left femoral artery was performed. 
Experimental cohorts of: Control (PBS) or DATS (100, 200 or 500 µg) was 
administered retro-orbitally twice daily following the hind limb ischemia surgery. 
More detailed methods are described in the supplement.  
 
Measurement of cystathionine γ -lyase (CSE) activity  
Tissues from the ischemic and non-ischemic hind limb of mice were collected at 
different time points of study. CSE activity was measured as we previously 
described.22  
 
Measurement of plasma hydrogen sulfide 
Hydrogen sulfide was measured using monobromobimane by RP-HPLC as we 
previously reported and reported in detail in the supplement.23  
 
Laser Doppler blood flow measurements 
Laser Doppler blood flows were measured using a Vasamedics Laserflo BPM2 
device in the ischemic limb of the mice pre and post-ischemia induction and 
indicated days post-ischemia as we have previously described.3  
 
Novadaq SPY imaging analysis 
The SPY imaging was performed to quantify collateral vessel perfusion as 
previously described.24  
  
Immunohistochemical staining of skeletal muscle tissues 
Immunohistochemistry staining with anti-smooth muscle actin (-SMA), anti-
CD31 antibodies and anti-HIF-1α was performed with nuclear stain DAPI (4′,6-
Diamidine-2′-phenylindole dihydrochloride), as we have previously described.3  
 
Isolation of monocytes 
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Bone marrow and whole blood from the mice were collected and processed from 
ischemic and non-ischemic hind limb of WT and CSE KO mice to isolate 
monocytes using a protocol as described elsewhere with minor modifications.25  
 
Isolation of endothelial progenitor cells (EPCs):  
EPCs were isolated from blood, bone marrow and skeletal muscles (ischemic 
and non-ischemic hind limbs) of WT, CSE KO mice (with or without DATS 
therapy) using protocols as described elsewhere with modifications.26, 27  
  
Measurement of cytokines expression  
IL-16, MCP-1, bFGF and VEGF levels were measured in gastrocnemius tissues 
using an ELISA kit from R&D Biosciences.  Briefly, PBS or DATS treated mice 
were euthanized at days 3 and gastrocnemius muscle tissues harvested and 
protein lysates made.  ELISA’s were performed according to manufacturer’s 
instructions. 
 
Statistical analysis 
Data were reported as mean ± standard error of the mean for all groups. 
Statistical analysis was performed with Mann‐ Whitney or Kruskal‐ Wallis 
analysis of variance with Dunn's multiple‐ comparison tests. A p-value of <0.05 
was required for statistical significance. Statistics were performed with GraphPad 
Prism 4.0 software.  
 
Results: 
H2S levels and CSE activity was increased in plasma and ischemic tissue 
Plasma free H2S was measured in WT and CSE KO mice and we found 
significant increases at day 3 and day 5 in WT mice but not in CSE KO mice 
(figure 1A). Free H2S levels in ischemic gastrocnemius muscle tissue were also 
significantly increased at days 5 and 7 in WT mice (figure 1B). Although there 
was no change in free H2S levels in plasma, a significant increase in free H2S 
levels in ischemic tissues was observed in CSE KO mice suggesting other 
compensatory pathways of H2S generation (CBS or 3-MST).  
Importantly we observed a significant increase in CSE activity of plasma 
and muscle tissues at days 3 and 5 after ligation in WT mice, (supplementary 
figure 1A & B), which was not observed in CSE KO mice. Increased CSE gene 
expression was also selectively observed in ischemic muscle tissues of WT but 
not in CSE KO (supplementary figure 1C & D). These results indicate that CSE 
activity and gene expression are induced during chronic tissue ischemia. 
 
Blood flow, blush rate and mature vessel density were decreased in 
ischemic tissues of CSE KO mice 
Restoration of blood flow to ischemic tissues is very important for its 
survival. We next measured limb blood flow and perfusion rates of WT and CSE 
KO mice at different time points after femoral artery ligation. Laser Doppler 
measurement of blood flow in ischemic tissue was significantly reduced in CSE 
KO mice compared to WT mice continuously after establishing tissue ischemia 
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(figure 1C). Similarly, acute changes in tissue perfusion (blush rate) by SPY 
angiogram were significantly reduced in CSE KO mice compared to WT mice at 
days 3, 5 and 7 after ligation (figure 1D). 
Formation of mature and functionally stable vessels is important for 
reperfusion of ischemic tissue. We next investigated the mature vessel density in 
WT and CSE KO mice by dual staining with anti CD31 and anti α-SMA 
antibodies.3 We observed a significant decrease in mature vessel density and 
angiogenic indices (figure 1E and F) in CSE KO mice suggesting the importance 
of the role of CSE/H2S during arteriogenesis in ischemic tissue. Vessel densities 
were significantly increased in ischemic tissue vessel densities compared to non-
ischemic controls of WT and CSE KO (supplementary figure 2). Representative 
images of blush rate and mature vessel density of WT and CSE KO mice are 
shown in supplementary figure 2A and B, respectively.  
 
DATS therapy rescues arteriogenesis and ischemic limb blood flow in CSE 
KO mice 
We next investigated the effect of exogenous H2S therapy using DATS. 
Parameters of arteriogenesis were closely examined since CSE/H2S appeared to 
significantly affect ischemic limb arteriogenesis activity. To understand the effect 
of DATS on ischemic blood flow recovery, we examined a range of DATS 
concentrations administered via retro-orbital injection (100, 200 and 500 µg/kg, 
twice daily) (supplementary figure 3A). Hind-limb blood flow in ischemic tissue 
was dose dependently increased by DATS in WT mice with a median dose of 
200 µg/kg. The pharmacokinetics of plasma free sulfide levels after injection of 
200 µg/kg DATS is reported in supplementary figure 3B. Administration of DATS 
significantly restored ischemia blood flow in both WT and CSE KO mice (figure 
2A). Similarly, blush rate detected by SPY angiogram was also augmented by 
DATS therapy both in WT and CSE KO mice (figure 2B).  
Collateral arteriolar growth and remodeling are crucial during 
arteriogenesis.28 We next examined the perfusion and diameter of the gracilis 
arteries in ischemic muscles with or without DATS therapy in WT and CSE KO 
mice. Figure 2C and D report that the diameter and number of perfused gracilis 
arteries were significantly less in CSE KO mice compared to WT mice, and were 
significantly increased after DATS therapy both in CSE KO and WT mice. 
Moreover, CD31 and α-SMA positive vessels were significantly increased after 
DATS therapy in ischemic tissue of CSE KO and WT mice (figure 2E and F).  
 
Effect of CSE expression on EPCs and monocytes during ischemic hind 
limb ischemia 
Bone marrow derived EPCs (BM-EPCs) in circulation and homed EPCs at 
the sites of ischemic event contribute to blood vessel formation.29 Therefore, to 
determine cellular mechanisms of H2S/CSE on arteriogenesis, we examined 
EPCs and monocytes from the circulation, skeletal muscle tissue and the bone 
marrow from WT and CSE KO mice. There was a significant increase in BM-
derived and circulating EPCs in the ischemic limb by day 3, which was further 
elevated upon DATS treatment (supplementary figure 4A & B). BM-derived EPCs 
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increased in the circulation and the skeletal muscle by days 5 and 7 post-ligation 
in WT mice, especially with DATS treatment (supplementary figure 4C). Induction 
of EPC’s was significantly reduced in CSE KO mice (supplementary figure 4 D, E 
& F). Moreover, a moderate increase in CSE KO mouse EPC induction in bone 
marrow and blood was observed with DATS treatment, but no increase in 
skeletal muscle tissues.   
Having observed a moderate effect of CSE/DATS on EPC function in 
ischemic tissue, we next examined whether monocyte recruitment was altered in 
CSE KO mice, as these cells critically regulate arteriogenesis.30 Monocyte 
infiltration was increased in WT mice but significantly attenuated in CSE KO mice 
compared to WT ischemic tissue.  Importantly, monocyte infiltration into ischemic 
tissue was increased with DATS therapy in WT mice and rescued in CSE KO 
mice (figure 3). Interestingly, ischemic tissue monocyte infiltration, CSE activity 
and H2S levels were significantly increased in circulating (supplementary figure 
5A & B) and BM-derived monocytes (supplementary figure 5C & D) of WT mice 
at day 3 after femoral artery ligation compared to sham WT mice. However, 
these changes were not observed in monocyte populations isolated from CSE 
KO mice. Moreover, we observed that under hypoxia, expression of CSE though 
adenoviral-CSE induces monocyte mediated endothelial cell proliferation in co-
culture, while inhibition of CSE with specific CSE-shRNA inhibits this response 
(supplementary figure 5E). 
 
CSE regulates ischemia and inflammatory gene expression 
Changes in mechanical forces after occlusion of the artery acts on 
endothelial cells lining the vascular walls and promotes the inflammatory signals 
required to start collateral formation.31, 32 We first evaluated the expression of 
HIF-1α in skeletal muscle tissue, which was elevated under ischemia in WT but 
not CSE KO mice and with DATS treatment in both WT and CSE KO mice 
(supplementary figure 6A). We next investigated the MCP-1 and IL-16 
expression in ischemic tissues of WT and CSE KO mice at day 3 after femoral 
artery ligation as they participate in arteriogenesis.17, 33 IL-16 levels were 
significantly increased in ischemic tissue of WT mice but not CSE KO mice; 
however, DATS therapy augmented IL-16 levels in both WT and CSE KO mice 
(supplementary figure 6B). No significant difference was observed in MCP-1 
levels of CSE KO mice compared to WT mice (data not shown). These data 
indicate the role of CSE/H2S on IL-16 expression during ischemia, which 
modulates arteriogenesis via recruitment of monocytes.  
Growth factors including VEGF and bFGF play significant roles during 
arteriogenesis and angiogenesis under ischemic conditions.34 VEGF and bFGF 
expression were attenuated in ischemic limbs of CSE KO compared to WT mice, 
but were augmented upon DATS therapy in both WT and CSE KO mice 
(supplementary figure 6C and D). Taken together, data here demonstrate that 
CSE/H2S increased IL-16, VEGF, and bFGF expression levels that are important 
for ischemic vascular remodeling.  
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CSE/H2S stimulates ischemic vascular remodeling and growth via NO 
dependent pathway 
NO is a prime mediator of vascular remodeling in ischemic tissue.35  Our 
previous work has shown that exogenous H2S stimulates ischemic 
revascularization in a NO/HIF-1 dependent pathway.3 Based on these findings, 
we sought to quantify plasma and tissue levels of NO in WT and CSE KO mice 
with DATS treatment (figure 4A and B). We observed a significant decrease in 
total NOx levels of plasma and muscle tissues at pre ligation, days 3, 5 and 7 
after ligation in CSE KO mice compared to WT mice. This indicates a role of 
CSE/H2S in modulating NO bioavailability that corroborates our earlier report. 
Importantly, this defect was recovered by DATS therapy in CSE KO mice, where 
a significant increase in NOx levels was observed in plasma and ligated muscle 
tissues (figure 4C and D). 
We examined whether DATS therapy restored blood flow and 
revascularization in WT and CSE KO mice via NO. Either the eNOS inhibitor L-
NAME or the NO scavenger cPTIO were used for these studies.  Both L-NAME 
and cPTIO blunted DATS restoration of ischemic hind limb reperfusion in WT 
mice (figure 5A & B). However, L-NAME treatment with DATS in CSE KO mice 
did not attenuate ischemic limb reperfusion (figure 5C); while cPTIO treatment 
did significantly inhibit DATS mediated ischemic limb reperfusion in CSE KO 
mice (Figure 5D) indicating that the effects of DATS in CSE KO mice is 
dependent on NO signaling, but not dependent on eNOS activity. Supplementary 
figure 7 further reports the effect of these treatments on DATS vascular 
remodeling as determined by CD31 versus α-SMA staining.   Inhibition of NO 
bioavailability via L-NAME or cPTIO significantly blunted tissue staining for these 
markers. 
 
Nitrite therapy increases NO bioavailability, ischemic limb blood flow and 
vascular density in CSE KO ischemic tissues 
Our laboratory has previously revealed that nitrite therapy selectively 
restores ischemic limb blood flow via its conversion back to NO that stimulates 
ischemic vascular remodeling.24 Given the significant deficiency of NO 
bioavailability in CSE KO mice, we sought to examine whether ischemic vascular 
remodeling in these animals was primarily due to reduced NO.  Thus, exogenous 
nitrite or control phosphate buffered saline was therapeutically administered to 
CSE KO mice with femoral artery ligation. We found in CSE KO mice that 165 
μg/kg nitrite robustly stimulates ischemic vascular remodeling by augmenting 
blood flow (figure 6A) and vascular density and proliferation (figure 6B and C) in 
ischemic tissues. Importantly, these effects of nitrite on ischemic vascular 
remodeling and proliferation were significantly inhibited by the NO scavenger 
cPTIO (figure 6B and C).  
Beneficial effects of nitrite and the inhibitory action by cPTIO were also 
observed with MAC-2 ischemic tissue staining for macrophages (figure 6D). We 
next examined whether the effect of macrophage recruitment was through a 
NO/IL-16 axis. We found that IL-16 levels were significantly increased in 
ischemic tissue of CSE KO with nitrite therapy, which was significantly reduced 
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by cPTIO (figure 6E). Likewise, VEGF levels were significantly increased with 
nitrite therapy in CSE KO mice and inhibited by cPTIO cotreatment (figure 6F). 
These data clearly demonstrate that defective NO bioavailability is a primary 
mediator of defective ischemic vascular remodeling in CSE KO mice. 
  
Discussion: 
Studies from ours and other laboratories have shown that H2S augment 
blood perfusion under ischemic condition by stimulating vascular remodeling and 
angiogenesis. 3, 36, 37 However, the role of CSE and endogenous H2S generation 
and subsequent molecular mechanisms related to vasculogenesis and collateral 
growth and remodeling in mouse ischemic hind limb has not been elucidated. In 
the present study, we have made several novel findings as illustrated in figure 7 
including: 1) CSE/H2S induces vasculogenesis through recruitment of EPCs and 
their homing to the site of ischemia, 2) arteriogenesis is impaired in ischemic 
tissue in the absence of CSE/H2S, which can be rescued by exogenous H2S 
therapy, 3) CSE/H2S rescues blood perfusion in ischemic tissue involving 
arteriogenesis via NO that is associated with differential monocyte recruitment 
and cytokine expression.  
H2S regulates many endothelial functions and the metabolism of signaling 
molecules that stimulate angiogenesis and arteriogenesis under ischemic 
conditions. 36, 38, 39 Currently, several donors of H2S including DATS, Na2S and 
NaHS have been used in different experimental settings. 3, 40, 41 In this study, we 
have used DATS as a H2S donor to perform rescue experiments. Our previous 
study has shown that Na2S augments ischemic angiogenesis by stimulating 
reduction of nitrite to NO and subsequently potentiating the expression of HIF-
1/VEGF in ischemic tissue.  In the present study, DATS therapy significantly 
rescued the blood flow and blush rate of ischemic tissue of CSE KO and WT 
mice following ischemia induction. The number and diameter of mature arterial 
collaterals and CD31 positive vessel density was also augmented after DATS 
therapy following ischemia. 
Monocyte recruitment at the injury site was also augmented by DATS 
therapy in CSE KO and WT mice following ischemia. Stimulation of the 
monocytic pathway also showed promising results for formation of collaterals 
after occlusion of main arteries.42, 43 Studies from different laboratories have 
suggested that recruitment of monocytes and their transformation into 
macrophages in the site of injury is important during arteriogenesis.42-44 Our data 
showed that monocyte recruitment was impaired during arteriogenesis in CSE 
KO mice, indicating that a functional CSE/H2S system facilitates monocyte 
recruitment for arteriole remodeling. We have also found that CSE activity and 
H2S generation in circulating and bone marrow derived monocytes following 
ischemia was significantly increased in WT mice. Together, it is clear that H2S 
plays a critical role in monocyte-mediated arteriogenesis and a lesser role for 
EPC-induced vasculogenesis in the murine femoral artery ligation model. 
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Different cytokines and signaling molecules including nitric oxide are 
involved in initiation of arteriogenesis. 16, 24, 45 However, in this study, we have 
shown for the first time that CSE/H2S is important for stimulating arteriogenesis. 
Our data have shown that formation of collaterals and subsequent blood flow are 
significantly attenuated in CSE KO compared to WT mice. Direct stimulation of 
smooth muscle cells and endothelial cells is pivotal to initiate arteriogenesis.15, 46 
Our present study has demonstrated that collateral arterial density and 
microvascular vessel density were significantly less in CSE KO mice subjected to 
hind limb ischemia compared to WT mice highlighting the role of CSE/H2S for 
vascular remodeling. 
We have recently reported that exogenous H2S therapy restores ischemic 
limb blood flow through angiogenesis mediated by nitrite/NO, suggesting a 
crosstalk between H2S and NO signaling pathways.3 However, the role played by 
NOS/NO in H2S mediated vasculogenesis remains unknown. Results from L-
NAME, cPTIO and VEGF-aptamer effects on blood flow indicate that H2S-
mediated revascularization depends at least in part on increased bioavailability of 
NO under ischemic conditions in WT mice. Interestingly, DATS restores blood 
flow in CSE KO mice inhibited by L-NAME/VEGF-aptamer; while the effect of 
cPTIO inhibition on blood flow was only partially restored. This indicates that in 
CSE KO mice there is a limited role played by eNOS/VEGF but NO plays a 
prominent role, corroborating our previous findings.3 
 
Our study shows that NO levels decrease in CSE KO mice after ischemia 
induction indicating the role of NO in CSE/H2S mediated vascular remodeling. 
Nitric oxide serves dichotomous roles for vascular remodeling, which is also 
referred as the NO paradox.47 At early stages of remodeling, NO stimulates 
recruitment of monocytes and expression of growth factors to promote vascular 
remodeling.48  Our previous study revealed that H2S also participates in ischemic 
angiogenesis via an NO dependent pathway involving microvascular growth.3 
With this study, we have further discovered that nitrite stimulates IL-16 
expression, recruits monocytes and increases VEGF expression in ischemic 
tissues of CSE KO mice indicating an important yet poorly understood 
relationship between sulfide bioavailability and NO metabolites. Further study is 
needed to better understand mechanistic relationships between sulfide and NO 
metabolite bioavailability and regulation of ischemic vascular remodeling. 
 
In conclusion, the findings of the present study indicate that dysregulation 
or deficiency of CSE as well as H2S generation have a significant effect on 
vasculogenesis and collateral formation that leads to recovery of blood perfusion 
in the mouse ischemic hind limb. However, exogenous H2S therapy induces 
vasculogenesis by activating HIF-1 mediated VEGF signaling for EPC 
recruitment and also rescues impaired arteriogenesis and blood perfusion via the 
IL-16/monocyte recruitment/bFGF/VEGF signaling pathway. NO plays a critical 
role in this response suggesting that these two molecules coordinately regulate 
ischemic vascular remodeling and restoration of blood flow in the mouse hind 
CVR-2015-246       Vascular Biology             CSE regulation of ischemic vascular remodeling 
 11 
limb.  Thus, it is possible that H2S bioavailability and metabolism may be 
important in the setting of peripheral arterial disease or critical limb ischemia. 
 
Significance 
The role of endogenous hydrogen sulfide generation and bioavailability for 
ischemic vascular growth and remodeling has not been known.  Our study 
provides critical new insight that increased endogenous cystathionine gamma 
lyase expression, activity, and hydrogen sulfide generation leading to 
augmentation of NO bioavailability is required for ischemic vascular remodeling 
that may be useful for future therapeutic revascularization approaches.  
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Figure Legends 
 
Figure 1- Blood perfusion and blood vessel density is impaired in CSE KO 
mice under ischemia. Panels A and B: Comparison of WT and CSE KO mice 
plasma and tissue free sulfide levels, respectively at different time points 
following hind limb ischemia induction. Panel C: Percent change in ischemic limb 
blood flow between WT and CSE KO mice as measured by laser doppler 
flowmetry. Panel D: Percent change in ischemic limb indocyanine green (ICG) 
blush rate between WT and CSE KO mice. Panel E: Immunohistochemical 
staining for vascular angiogenic index (CD31/DAPI) between WT and CSE KO 
ischemic muscle. Panel F: Immunohistochemical staining for arterial vessels 
(SMA/DAPI) between WT and CSE KO mice. n=7 per cohort, *p<0.05. 
 
Figure 2- DATS therapy induces blood flow and collateral formation. Panel 
A shows changes in WT or CSE KO mouse ischemic limb blood flow with PBS or 
DATS (200 μg/kg, twice daily) over time. Panel B illustrates ICG blush rate 
changes between WT or CSE KO mice given PBS or DATS therapy. Panels C 
and D report quantitative measurement of number and diameter of gracilis 
collaterals between WT and CSE KO mice with PBS or DATS therapy, 
respectively. Panels E and F report angiogenic index (CD31/DAPI) and arterial 
vessel staining (SMA/DAPI) between WT and CSE KO mice with PBS or DATS 
therapy, respectively. n=5 per cohort, *p<0.05. 
 
Figure 3- Monocyte recruitment is inhibited in CSE KO hind limb ischemia. 
Panel A shows representative photomicrographs of MAC-2 and DAPI counter-
stained ischemic skeletal muscle sections of PBS or DATS treated WT and CSE 
KO mice at day 3. Panel B illustrates quantitative image analysis of ischemic 
muscle MAC-2/DAPI staining between WT and CSE KO mice treated with PBS 
or DATS. n=5 per cohort, *p<0.05. 
 
Figure 4- CSE KO mice have reduced NOx levels that are restored by DATS 
treatment. Panel A shows levels of total plasma NOx at different time points 
between WT and CSE KO mice. Panel B illustrates ischemic muscle tissue total 
NOx at different time points between WT and CSE KO mice. Panel C reports 
plasma total NOx levels in CSE KO mice treated with PBS or DATS therapy over 
time. Panel D shows ischemic muscle tissue total NOx levels in CSE KO mice 
with PBS or DATS therapy over time. n= 5 per genotype or treatment cohort. 
*p<0.05 versus pre-ligation value, #p<0.05 WT versus CSE KO in panels A & B 
and PBS versus DATS in panels C & D. 
 
Figure 5- DATS mediated restoration of blood flow is NO dependent. Panels 
A and B: DATS mediated changes in ischemic limb blood flow of WT mice with L-
NAME (LN) or NO scavenger (CPTIO), respectively. Panels C and D: DATS 
mediated changes in ischemic limb blood flow of CSE KO mice with L-NAME 
(LN) or NO scavenger (CPTIO), respectively. n=6 per cohort, *p<0.05. 
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Figure 6- Nitrite restores blood flow in CSE KO mice. Panel A reports percent 
change in ischemic limb blood flow of CSE KO mice given PBS, nitrite (165 
g/kg) or nitrite + cPTIO (1 mg/kg) twice daily therapy. Panel B shows 
quantitative measurement of angiogenic index (CD31/DAPI) staining of CSE KO 
ischemic muscle treated with nitrite or nitrite + cPTIO therapy. Panel C reports 
quantitative measurement of cell proliferation index (Ki67/DAPI) staining of CSE 
KO ischemic muscle treated with nitrite or nitrite + cPTIO therapy. Panel D shows 
tissue macrophage (MAC-2/DAPI) staining of CSE KO ischemic muscle treated 
with nitrite or nitrite + cPTIO therapy. Panels E and F illustrate IL-16 and VEGF 
levels in CSE KO ischemic tissues with nitrite or nitrite + cPTIO therapy, 
respectively. n=5 per cohort, *p<0.05. 
 
Figure 7- Summary of CSE/H2S regulation of ischemic vascular remodeling 
pathways. Femoral artery ligation and subsequent limb chronic ischemia leads 
to increased CSE expression, activity and H2S generation. Genetic deficiency of 
CSE inhibits ischemia-mediated induction of H2S dependent stimulation of NO 
bioavailability and down stream activation of cytokine and cellular arteriogenesis 
and angiogenesis pathways. 
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DETAILED METHODS 
Materials: 
Anti-Ki67, SDF-1 and HIF-1 antibodies were obtained from Abcam Inc 
(Cambridge, MA, USA). Anti-CD31 antibody was obtained from BD Biosciences 
(San Jose, CA, USA). CD34 and Flk-1 antibodies were purchased from 
eBioscience. Vectashield plus DAPI was purchased from Vector Laboratories. All 
secondary fluorophore conjugated antibodies were bought from Jackson 
Immunoresearch Inc (West Grove, PA, USA). MCP-1 and IL-16, bFGF and 
VEGF ELISA kits were purchased from R & D system. All general chemicals and 
tissue culture reagents were obtained from Sigma Chemicals. The murine MS-1 
endothelial cell line was obtained from ATCC. 
Animals and experimental procedures  
Twelve weeks old C57BL/6J (WT) and Cystathionine γ-lyase knock out 
(CSE KO) were used in this study.  WT mice were purchased from the Jackson 
laboratory and CSE KO mice have been generated and are breeding in Dr. 
Kevil’s laboratory. Mice were housed at the Association for Assessment and 
Accreditation of Laboratory Animal Care, internationally accredited Louisiana 
State University Health Science Center-Shreveport animal resource facility, and 
maintained in accordance with the National Research Council’s Guide for Care 
and Use of Laboratory Animals. All animal studies were approved by the 
institutional animal care and use committee (icook # P-12-011). 
Induction of mouse hind limb ischemia upon femoral artery ligation 
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 Permanent hind limb ischemia was induced in WT and CSEKO mice as 
previously described.1, 2 Briefly, mice were anesthetized with an intraperitoneal 
injection of ketamine (100 mg/kg) and xylazine (8 mg/kg). Aseptic surgery was 
performed by a linear incision in the left groin, and then the left common femoral 
artery was ligated distal to profunda femoris artery, cut, and excised to obtain a 
mouse model of severe hind limb ischemia.  Immediate pallor was observed in 
the distal hind limb following ligation of the artery using 5-0 silk.  Following 
surgery, the mice were randomly assigned to different experimental groups and 
treated for 3 weeks.  Group profiles (n=8 unless otherwise stated): Control (PBS), 
or DATS (100, 200 and 500 µg) was administered retro-orbitally twice daily 
following the hind limb ischemia surgery until the end of the study. 
 
Measurement of Cystathionine γ-lyase (CSE) activity  
 
Tissues from the ischemic and non-ischemic hind limb of mice were 
collected at different time points of study. CSE activity (loss of cystathionine) was 
measured as previously described.3 Briefly, tissue lysates were incubated with a 
mixture of 2mM cystathionine, 0.25 mM pyridoxal 5’-phosphate in 100 mM Tris-
HCl buffer (pH 8.3) for 60 min at 37°C. 10% Trichloroacitic acid was then added 
into the reaction mixture. After centrifugation of this mixture, the supernatant was 
mixed vigorously with 1% ninhydrin reagent and incubated for 2 minutes in 
boiling- water bath. The heated solution was then cooled down on ice for 2 
minutes using a smartSpect Plus spectrophotometer (Bio-Rad). The activity of 
CSE was measured by cystathionine consumption and expressed as nanomoles 
of cystathionine utilized per mg of total protein per hour of incubation. 
 4 
Measurement of hydrogen sulfide 
 
Hydrogen sulfide was measured using monobromobimane by RP-HPLC 
as previously reported.4 Briefly, mice were anesthetized with intraperitoneal (i.p) 
injection of ketamine/xylazine (100 and 8 mg/kg), blood and gastrocnemius 
skeletal muscle tissues were collected from WT and CSEKO mice at different 
time points following ischemia.  
Measurement of free sulfide: Thirty μl of sample was treated with 70 µl of Tris-
HCl (pH 9.5, 0.1 mM DTPA), followed by 50 µl of MBB solution (10 mM) at 1% 
oxygen in a hypoxic chamber at room temperature and incubated for 30 minutes. 
The reaction was terminated with 50 µl of stop solution (200 mM 5-sulfosalicylic 
acid). Lastly, SDB reaction product was measured using a Shimadzu 
Prominence Ultra Fast HPLC system equipped with a fluorescence detector (λex 
390 nm and λem 475 nm) coupled with an Eclipse XDB-C18 column (4.6 × 
250 mm). 
Measurement of acid-labile and bound sulfane sulfur pools:  
Acid-labile sulfide was released by incubating samples in an acidic solution (pH 
2.6, 100 mM phosphate buffer, 0.1 mM DTPA), in an enclosed system to contain 
volatilized hydrogen sulfide, then trapped in 100 mM Tris–HCl buffer (pH 9.5, 
0.1 mM DTPA). The bound sulfane sulfur pool was measured by incubating the 
sample with 1 mM Tris (2-carboxyethyl) phosphine (TCEP) in 100 mM phosphate 
buffer at pH 2.6 with 0.1 mM DTPA, and sulfide measurement was performed in 
a manner analogous to that described above.  
Acid-labile pool was determined by:  
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(Value obtained by the acid-liberation protocol) – (value from free hydrogen 
sulfide).  
Bound sulfane sulfur pool was determined by: 
(Value from TCEP plus acidic conditions) – (value from hydrogen sulfide 
measurement from the acid-liberation protocol alone) 
 
Novadaq SPY Imaging Analysis 
The SPY imaging was performed to quantify collateral formation as 
previously described.2 Briefly, mice were anesthetized with inhaled isofluorane 
and the bolus injection of vascular contrast dye, indocyanine green (ICG, 30 μL, 
165μM concentration) was administered retro-orbitally, and angiograms were 
recorded for one minute.  Angiograms were taken before and after ligation of 
femoral artery as well as days 1, 3, 5, 7 post- ligation of either PBS or DATS 
treated animals. Collateral vessel numbers and diameters were measured using 
morphometric analysis tools in Nikon Elements software.  
Immunohistochemical Staining of skeletal muscle tissues 
 Immunohistochemistry staining with anti-smooth muscle actin, anti-CD31 
antibodies, CSE, HIF-1α, SDF was performed with nuclear stain DAPI (4′,6-
Diamidine-2′-phenylindole dihydrochloride), as we have previously described.2  
Gastrocnemius muscle from ischemic and non-ischemic hind limbs of WT and 
CSEKO mice were dissected and embedded in OCT freezing medium, frozen, 
and cut into 5 µm sections. The slides were then fixed at −20°C in 95% 
ethanol/5% glacial acetic acid for 1 h. Slides were blocked with 5% horse serum 
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and stained with anti-CD31 antibody (1:200 dilution), and primary antibody 
against SMA (smooth muscle actin, 1:500 dilution), and incubated at 37°C for 1 
h. Slides were then washed with PBS, and Cy3 conjugated anti-rat secondary 
antibody  (1:250 dilution), and Alexafluor 488 conjugated anti-mouse secondary 
antibodies (1:500 dilution) were added, and incubated at room temperature for 1 
h. Slides were then mounted using Vectashield DAPI mounting medium. At least 
four slides per hind limb with three sections per slide were made for vascular 
staining and analysis. A minimum of two fields was acquired per section of 
muscle. Pictures were taken with a Hamamatsu digital camera using a Nikon TE-
2000 epifluorescence microscope (Nikon Corporation, Japan) at ×200 
magnification. Simple PCI software version 6.0 (Compix Inc., Sewickley, PA, 
USA) was used to analyze the area of CD31 and SMA staining of arterial 
vessels. 
Isolation of monocytes 
Bone marrow and whole blood from the mice were collected and 
processed from ischemic and non-ischemic hind limb of WT and CSEKO mice to 
isolate monocytes using a protocol as described elsewhere with minor 
modifications.5 Monocyte isolation was then performed using Easy Sep 
monocyte enrichment kits according to manufacturer manual instruction. Briefly, 
after preparing the cell suspension at a concentration of 1 x 108 cells/ml in 
recommended medium, EasySep™ Mouse Monocyte Enrichment Cocktail of 
biotinylated antibody at 50 μL/mL of cells were added, well mixed and incubated 
in refrigerator (2-8°C) for 15 minutes. Cells were washed, centrifuged at 300 x g 
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for 10 minutes and resuspended with recommended medium. EasySep™ Biotin 
Selection Cocktail was then added at 60 μL/mL of cells, well mixed and 
incubated again in refrigerator (2-8°C) for 15 minutes. EasySep™ D Magnetic 
Particles were added at 150 μL/mL cells, well mixed and incubated in refrigerator 
(2-8°C) for 10 minutes. The tube containing cell suspension (without cap) was 
then placed into the magnet and set aside for 5 minutes. Lastly, separated 
monocytes were collected into new tube by inverting the magnet and tube with 
one continuous motion. 
Isolation of endothelial progenitor cells (EPCs):  
EPCs were isolated from blood, bone marrow and skeletal muscles of WT, 
CSEKO mice (with or without DATS therapy) using protocols as described 
elsewhere with modifications- 
a. EPCs from blood: Circulating endothelial progenitor cells (EPCs) in 
blood was isolated as described elsewhere.6 Briefly, 1ml of blood was collected 
from the mice through retro orbital bleeding. Isolated blood was centrifuged 
under refrigeration (2-8°C) at 840 x g for 30 minutes. The middle yellow colored 
layer that includes mononuclear cells was collected and resuspended in FACS 
buffer for further analysis.  
b. EPCs from bone marrow: EPCs will be cultured from mononuclear 
cells obtained from bone marrows of ischemic femurs as described elsewhere.6 
Briefly, bone marrow (BM) cells will be harvested by flushing the femurs of 
ischemic limbs from mice. Cells will be centrifuged and collected in media for 
further analysis. 
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c. EPCs from skeletal muscle: EPCs will be cultured from muscle 
tissues as described elsewhere.7 Briefly, gastrocnemius muscle tissues will be 
excised, torn to small pieces and treated with collagenase II, Collagenase D and 
Dispase II with intermittent washing and centrifugation at 700 x g for 10 minutes. 
Cells will be filtered through a 40μM cell strainer and cells are collected for 
further analysis.  
To characterize and quantify the number of EPCs cells isolated from 
blood, skeletal muscle and bone marrow were labeled with Flk1-PE and CD34-
FITC antibodies (BD biosciences) with corresponding isotype controls. Cells 
were then fixed in 1% paraformaldehyde to quantify further for flow cytometric 
analysis using FACS Calibur flow cytometer (BD biosciences). 
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Supplementary Figure Legends 
 
Supplementary figure 1- CSE activity (cystathionine consumption) was increased in 
ischemic limb of WT mice. Panels A and B report the CSE activity in plasma and 
ischemic muscle tissues of WT and CSE KO mice at different time points following 
femoral artery ligation. Panel C illustrates time-dependent mRNA expression in ischemic 
and non-ischemic limbs of WT following femoral artery ligation. Panel D shows fold 
change in CSE mRNA expression in tissues from WT and CSE KO mice at day 7. n=4 
per cohort, *p<0.05. 
 
Supplementary figure 2- CSE KO ischemic limbs have reduced collateral formation. 
Panel A shows representative SPY angiographic images of ischemic WT and CSE KO 
collateral vessels at pre and post-ligation and day 3. Red arrows indicate perfused vessels. 
Panel B shows representative images of mature vessel density staining (red= CD31, 
green= -SMA, blue= DAPI) in ischemic tissues of WT and CSEKO mice 3 days 
following ischemia induction. Areas of yellow indicate colocalization of CD31/-SMA 
vessels. 
 
Supplementary figure 3- DATS therapy through retro orbital restores the blood flow in 
ischemic tissues of WT and CSE KO mice. Panel A illustrates the pharmacokinetics of 
plasma total sulfide in WT mice after retro-orbital injection with 200 g/kg DATS 
comparing ro vs ip delivery; while Panel B illustrates the pharmacokinetics of total 
sulfide in skeletal muscle tissue. Panel C reports dose dependent blood flow data 
following induction of hind limb ischemia over a range of DATS dose therapies (100, 
200 or 500 g/kg) in WT mice. n=7 per cohort, *p<0.05. 
 
Supplementary figure 4: Differences in EPC recruitment between WT and CSE KO 
mice. Panels A-C report percentage of EPCs (Flk-1/CD34 positive cells) in bone marrow 
(BM), blood and skeletal muscle (SKM) from sham and ischemic limbs (PBS/DATS) of 
WT mice, respectively. Panels D-F report percentage of EPCs (Flk-1/CD34 positive 
cells) in bone marrow (BM), blood and skeletal muscle (SKM) from sham and ischemic 
limbs (PBS/DATS) of CSE KO mice, respectively. EPC analysis was performed at Day 
0, 3, 5 and 7. n=4 per cohort, *#@p<0.05. 
 
Supplementary figure 5: CSE deficiency reduces monocyte H2S production. Panels A 
and B report circulating monocyte CSE activity and H2S production from WT and CSE 
KO mice from sham (no FAL) versus ischemic (FAL) treated mice. Panels C and D 
report bone marrow monocyte CSE activity and H2S production from WT and CSE KO 
mice from sham (no FAL) versus ischemic (FAL) treated mice. n=6 per cohort, *p<0.05. 
Panel E reports BrdU proliferation of endothelial cells under normoxia or hypoxic 
conditions treated with conditional media from WEHI 274.1 monocytes treated with PBS 
(control), CSE ShRNA or adenoviral CSE (adCSE). n=7 per treatment, *#p<0.05. 
 
Supplementary figure 6: CSE deficiency blunts ischemic tissue HIF-1, IL-16 and 
growth factor expression that is rescued by DATS. Panel A shows expression of HIF-1 
in ischemic and non-ischemic skeletal muscle tissues of WT and CSE KO mice with PBS 
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or DATS treatment. Panel B reports ischemic muscle tissue levels of IL-16 between WT 
and CSE KO mice treated with PBS or DATS. Panel C illustrates ischemic muscle tissue 
levels of bFGF between WT and CSE KO mice treated with PBS or DATS. Panel D 
shows ischemic muscle tissue levels of VEGF between WT and CSE KO mice treated 
with PBS or DATS. n=5 per genotype and treatment cohort. The grey dashed line in 
panels B, C and D indicate WT NI PBS control cytokine levels. 
*p<0.05 versus WT sham, #p<0.05 NI vs Isch, @p<0.05 versus WT NI. 
 
Supplementary figure 7: NO regulates DATS mediated vascular remodeling. Panel A 
shows ischemic muscle CD31/DAPI ratio of WT or CSE KO mice treated with DATS + 
L-NAME or cPTIO. Panel B reports ischemic muscle -SMA/DAPI ratio of WT or CSE 
KO mice treated with DATS + L-NAME or cPTIO. Panel C shows representative images 
from sections of ischemic limbs treated with DATS + L-NAME or cPTIO in WT (upper 
panel) and CSE KO (lower panel). n=5 per genotype or treatment cohort. *p<0.05 versus 
DATS therapy alone, #p<0.01 versus DATS therapy alone. 
 
